Anika Therapeutics, Inc.

NASDAQ:ANIK

16.33 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993
Revenue 166.662156.236147.794130.457114.61105.555113.42103.37992.999105.59575.08171.35964.77955.55740.13635.7830.8326.84129.83526.46615.40413.18711.31216.33513.513.9121.23.44.72.2
Cost of Revenue 63.57462.6664.85161.43128.74731.2827.36424.02721.05320.9322.76528.98926.78423.82713.6713.18911.88111.11811.1449.9498.0058.1098.2298.6735.35.24.40.72.83.71.9
Gross Profit 103.08893.57682.94369.02685.86374.27586.05679.35271.94684.66552.31642.3737.99531.7326.46522.59118.94915.72318.69116.5177.3995.0783.0837.6628.28.77.60.50.610.3
Gross Profit Ratio 0.6190.5990.5610.5290.7490.7040.7590.7680.7740.8020.6970.5940.5870.5710.6590.6310.6150.5860.6260.6240.480.3850.2730.4690.6070.6260.6330.4170.1760.2130.136
Reseach & Development Expenses 32.6928.18227.32723.43116.66518.1918.78710.7328.9878.1447.065.3886.1696.8758.1827.3994.3653.6164.7314.0872.5953.9284.2813.264.22201.31.50
General & Administrative Expenses 0000034.33621.5418.01314.82515.07312.93614.72917.85917.31810.54510.9657.9976.6795.4096.0424.2094.4256.2134.18832.72.100.90.71.9
Selling & Marketing Expenses 0000000000000000000000000000000
SG&A 95.84784.79474.09660.06334.9534.33621.5418.01314.82515.07312.93614.72917.85917.31810.54510.9657.9976.6795.4096.0424.2094.4256.2134.18832.72.12.60.90.71.9
Other Expenses 62.1900000000002,537.988002,151.854000000001.1981.10.80.30.60.30.20.3
Operating Expenses 191.475112.976101.42383.49451.61552.52640.32728.74523.81223.21819.99620.11724.02724.19218.72718.36512.36110.29510.1410.1296.8048.35310.4948.6468.35.54.43.22.52.42.2
Operating Income -87.639-19.4-18.48-14.46834.24821.74945.72950.60748.13461.44732.60719.71513.9677.5385.5874.2276.5875.4278.5516.3880.595-3.274-7.411-0.983-0.13.23.2-2.7-1.9-1.4-1.9
Operating Income Ratio -0.526-0.124-0.125-0.1110.2990.2060.4030.490.5180.5820.4340.2760.2160.1360.1390.1180.2140.2020.2870.2410.039-0.248-0.655-0.06-0.0070.230.267-2.25-0.559-0.298-0.864
Total Other Income Expenses Net 2.3120.654-0.188-0.3021.8731.4580.4730.2630.120.058-0.127-0.188-0.182-0.195-2.2260.4992.1012.1011.2410.3890.1440.2390.6621.1731.380.70.20.100.10
Income Before Tax -85.327-18.7462.427-28.62436.12123.20746.20250.8748.25461.50532.4819.52713.7857.3435.5124.7258.6887.5289.7926.7770.739-3.035-6.7490.189-0.14.43.4-2.60-1.3-1.9
Income Before Tax Ratio -0.512-0.120.016-0.2190.3150.220.4070.4920.5190.5820.4330.2740.2130.1320.1370.1320.2820.280.3280.2560.048-0.23-0.5970.012-0.0070.3170.283-2.1670-0.277-0.864
Income Tax Expense -2.66-3.887-1.707-4.6428.9284.48514.38618.32317.49623.18611.9057.775.3183.0271.8251.0962.6532.9243.899-4.413-0.0880.0050.0090.0162.20.10.1-0.10.1-0.1-0.3
Net Income -82.667-14.8594.134-23.98227.19318.72231.81632.54730.75838.31920.57511.7578.4674.3163.6883.6296.0354.6045.89311.190.827-3.04-6.7580.174-2.54.33.3-2.7-2-1.4-1.6
Net Income Ratio -0.496-0.0950.028-0.1840.2370.1770.2810.3150.3310.3630.2740.1650.1310.0780.0920.1010.1960.1720.1980.4230.054-0.231-0.5970.011-0.1850.3090.275-2.25-0.588-0.298-0.727
EPS -5.64-1.020.29-1.691.931.32.182.222.062.611.460.890.650.340.320.320.550.430.570.980.08-0.31-0.680.018-0.260.380.6-0.56-0.61-0.45-0.51
EPS Diluted -5.64-1.020.28-1.691.891.272.112.152.012.511.390.820.620.320.320.320.530.410.520.980.08-0.31-0.680.018-0.240.340.44-0.56-0.61-0.45-0.51
EBITDA -11.232-4.9132.615-12.82934.24827.65950.01954.34151.90961.44732.03326.77817.9710.85811.1845.667.4065.8129.0114.5261.601-2.179-6.1770.2141.0983.3733.5-2.1-1.6-1.2-1.6
EBITDA Ratio -0.067-0.124-0.268-0.0050.2990.2060.4030.490.5180.5820.4270.3470.2770.1950.2790.1580.240.2170.3020.2680.104-0.165-0.5460.0130.0590.1940.267-1.833-0.471-0.277-0.727